Rheumatology Medical News about Juvenile dermatomyositis

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment
Best Practice & Research: Clinical Rheumatology, 10/28/09

Wedderburn LR et al. – Juvenile dermatomyositis (JDM) is a rare, potentially life–threatening systemic autoimmune disease primarily affecting muscle and skin. Aggressive treatment approaches, including multiple initial therapies, as well as new drugs and biological therapies for refractory disease, offer promise of improved outcomes and less corticosteroid–related toxicity.

<< Previous
Improving the management of paediatric rheumatic diseases...

Next >>
Progress in osteoporosis and fracture prevention: focus on...